Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

Completed · Phase 3 · Has a placebo group

Conditions studied: Hypertriglyceridemia

In brief

The primary objective is to determine the efficacy of AMR101 (ethyl icosapentate) compared to placebo in lowering fasting triglyceride levels in patients with very high fasting triglyceride levels ≥ 500 and ≤ 2000 mg/dL.

Key facts

Study ID

NCT01047683

Run by

Amarin Pharma Inc.

People needed

229

Starts

2009-12-01

Expected to finish

2011-07-01

Last updated by the study team

2022-04-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women, ages >18
• Fasting triglyceride ≥500 mg/dL and ≤2000 mg/dL
• Provide written informed consent and authorization for protected health information disclosure

You may not qualify if…

• Women who are pregnant or lactating, or planning to become pregnant
• Use of non-statin lipid-altering drugs which cannot be stopped including fibrates, niacin, fish oil and other products containing omega-3 fatty acids or other dietary supplements with potential lipid-altering effects
• History of pancreatitis
• History of bariatric surgery or currently on weight loss drugs
• Uncontrolled hypertension (BP > 160/100)
• HIV infection or on treatment with HIV-protease inhibitors, cyclophosphamide,or isotretinoin
• Consumption of more than 2 alcoholic beverages per day
• History of cancers (except if been disease free for >5 years OR history was basal or squamous cell skin cancer)
• Participation in another clinical trial involving an investigational agent in the last 30 days
• Other parameters will be assessed at the study center to ensure eligibility for this study.

Where it is running

• Amarin Investigational Site — Golden, Colorado, United States
• Amarin Investigational Site — Miami, Florida, United States
• Amarin Investigational Site — Miami, Florida, United States
• Amarin Investigational Site — Ocala, Florida, United States
• Amarin Investigational Site — Addison, Illinois, United States
• Amarin Investigational Site — Chicago, Illinois, United States
• Amarin Investigational Site — Louisville, Kentucky, United States
• Amarin Investigational Site — Butte, Montana, United States
• Amarin Investigational Site — Raleigh, North Carolina, United States
• Amarin Investigational Site — Winston-Salem, North Carolina, United States
• Amarin Investigational Site — Cincinnati, Ohio, United States
• Amarin Investigational Site — Cincinnati, Ohio, United States
• Amarin Investigational Site — Lyndhurst, Ohio, United States
• Amarin Investigational Site — Tulsa, Oklahoma, United States
• Amarin Investigational Site — Corpus Christi, Texas, United States
• Amarin Investigational Site — Houston, Texas, United States
• Amarin Investigational Site — Richmond, Virginia, United States
• Amarin Investigational Site — Aalborg, Denmark
• Amarin Investigational Site — Herlev, Denmark
• Amarin Investigational Site — Oulu, Finland
• Amarin Investigational Site — Dresden, Germany
• Amarin Investigational Site — Giessen, Germany
• Amarin Investigational Site — Magdeburg, Germany
• Amarin Investigational Site — München, Germany
• Amarin Investigational Site — Sacramento, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.